Company intelligence
ZeClinics
ZeClinics is a Contract Research Organization (CRO) using zebrafish for drug discovery and biomedical research.
About ZeClinics
ZeClinics is a leading zebrafish-expert CRO, dedicated to tailoring innovative solutions for understanding human disease and advancing drug and target discovery. Our mission is to accelerate research by providing deep in vivo insights, enabling reliable safety and efficacy assessments of new drugs and chemical compounds to reach the market faster. We challenge the traditional discovery process by integrating our expertise in zebrafish biology with cutting-edge lab automation and artificial intelligence. As specialists in CRISPR genome editing, ZeClinics creates custom genome-edited zebrafish models to accurately mimic human diseases. This approach allows us to evaluate the biomedical relevance of candidate compounds and genes in vivo. Our unique zebrafish platforms bridge the gap between cell cultures and mammalian models, offering faster, cost-effective investigations that emphasize proof-of-principle experiments for rapid go/no-go decision making, thereby accelerating the early-stage development of new compounds. ZeClinics offers essential services to pharmaceutical, biotech, nutraceutical, and agrochemical companies, as well as academic research institutions worldwide, helping to enhance and expedite their R&D efforts.
Verified activity
Signals from ZeClinics
11 published signals
Research & Knowledge
ZeClinics published a study by Patten et al. using zebrafish models to evaluate the efficacy of pimozide for ALS.
Reported by ZeClinics
Products & Services
ZeClinics has built a CNS model portfolio to help researchers screen compounds with shorter turnaround times compared to mammalian models.
Reported by ZeClinics
Research & Knowledge
ZeClinics narrowed the field of genetic cardiomyopathies to 20 promising hits, leaving 5 candidates worth the cost of a rodent study instead of 20.
Reported by Simone Calzolari
Research & Knowledge
ZeClinics narrowed the field of genetic cardiomyopathies to 20 promising hits using a screen of 300 compounds against human cardiomyocyte models of dilated and hypertrophic cardiomyopathy.
Reported by Simone Calzolari
Research & Knowledge
ZeClinics built custom zebrafish genetic models for both dilated and hypertrophic cardiomyopathy using CRISPR/Cas9, validated them against human phenotypes, and ran 20 compounds through high-throughput screening.
Reported by Simone Calzolari
Research & Knowledge
ZeClinics built a full pipeline from zebrafish screening through rodent testing, saving $1.5 million and 24 months instead of 14 months.
Reported by Simone Calzolari
Legal & Regulatory
ZeClinics notes that in March 2026, the FDA issued a draft guidance about General Considerations for the Use of New Approach Methodologies in Drug Development, explicitly mentioning zebrafish as an example.
Reported by Simone Calzolari
Presence & Recognition
ZeClinics team members will be in Vienna from September 13 to 16 for the EUROTOX Congress at the Austria Center Vienna, alongside a large part of the European toxicology community.
Reported by Simone Calzolari
Products & Services
ZeClinics has built a CNS model portfolio to help researchers screen compounds with shorter turnaround times compared to mammalian models.
Reported by Simone Calzolari
Research & Knowledge
ZeClinics published a study by Patten et al. using zebrafish models to evaluate the efficacy of pimozide for ALS, with mutant zebrafish exhibiting familial ALS symptoms.
Reported by Simone Calzolari
Research & Knowledge
ZeClinics published a zebrafish cerebral atlas created by researchers from the Max Planck Institute to provide standardized brain region annotations, traced single neurons, and a compendium of markers and transgenes.
Reported by ZeClinics